Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413304 | 0.93 | RAB9A (0.44) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL2183468 | 0.87 | NFKB1 (0.42) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL2181830 | 0.87 | LMNA (0.42) | NPC1KMT2ANFKB1NFKB2RELA | |
| SCHEMBL12413324 | 0.80 | ESR1 (0.39) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL12413374 | 0.80 | LMNA (0.40) | KMT2ANFKB1NFKB2RELAESR1 | |
| SCHEMBL12503744 | 0.78 | RAB9A (0.40) | NPC1TP53RAB9ASMN1; SMN2PKM | |
| SCHEMBL2182453 | 0.78 | ESR1 (0.48) | CYP19A1ESR1ESR2LMNACYP11B1 | |
| SCHEMBL2182312 | 0.77 | CA2 (0.44) | TP53RAB9ASMN1; SMN2PKMKMT2A | |
| SCHEMBL2180009 | 0.77 | CA2 (0.44) | TP53RAB9ASMN1; SMN2PKMKMT2A | |
| SCHEMBL12503753 | 0.76 | CA2 (0.37) | NPC1TP53RAB9ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| WO-2009003229-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NFE2L2, PTGS2, PTGES2 | NPC1 1314/4885TP53 2490/4885RAB9A 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.